Laury Poulain

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.

Journal: Leukemia
Published: October 11, 2022

RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.

RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.

Journal: Leukemia
Published: December 07, 2021

AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia.

AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia.

Journal: Cancers
Published: September 14, 2021

AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.

AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.

Journal: Cell reports
Published: June 15, 2021

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.

Journal: Frontiers in oncology
Published: March 29, 2019

Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia

Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia

Journal: Medecine sciences : M/S
Published: October 21, 2015

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Journal: Oncotarget
Published: August 17, 2015

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Journal: Science advances
Published: February 23, 2015

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Journal: Blood
Published: January 14, 2015

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Journal: Cell reports
Published: December 26, 2014

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Journal: Blood
Published: September 10, 2013

Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.

Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.

Journal: British journal of haematology
Published: May 24, 2013
Showing 1-12 of 12

Last Updated: 09/26/2026